`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`C.A. No. 15-272 (GMS)
`CONSOLIDATED
`
`)))))))))))))
`
`FOREST LABORATORIES, LLC, FOREST
`LABORATORIES HOLDINGS, LTD.,
`MERCK KGaA and MERCK PATENT
`GESELLSCHAFT MIT BESCHRÄNKTER
`HAFTUNG,
`
`Plaintiffs,
`
`v.
`
`ACCORD HEALTHCARE INC.,
`
`Defendant.
`
`STIPULATION AND ORDER
`
`IT IS HEREBY STIPULATED by the parties, subject to the approval of the Court, that
`
`the following constructions shall be given to the claim terms in the listed patents below:
`
`Claim Term
`
`Patent/Claim
`
`Stipulated Construction
`
`“administer”
`“administered”
`“administering”
`
`’020 patent, claim 2;
`’195 patent, claims 1-2;
`’804 patent, claim 1;
`’921 patent, claims 10, 12-14
`
`“deliver[ed/ing] into the body”
`
`“corresponding to”
`
`’804 patent, claims 1-3
`
`“exhibits the following
`XRD data”
`
`’020 patent, claim 1
`
`“matching the values recited in the
`claims, including the error ranges
`stated therein”
`
`“show all the following peaks and
`intensities, including an error
`range of +/- 0.1o for the two-theta
`values”
`
`“A method of treating
`a patient suffering
`from a depressive
`disorder, an anxiety
`disorder, a bipolar
`
`‘020 patent, claim 2
`‘921 patent, claims 10, 12-14
`
`Entire preamble is limiting
`
`Merck 2014
`Argentum v. Merck
`IPR2018-00423
`
`
`
`Case 1:15-cv-00272-GMS Document 101 Filed 10/18/16 Page 2 of 6 PageID #: 1631
`
`Patent/Claim
`
`Stipulated Construction
`
`Claim Term
`disorder, mania,
`dementia, a substance-
`related disorder, a
`sexual dysfunction, an
`eating disorder,
`obesity, fibromyalgia,
`a sleeping disorder, a
`psychiatric disorder,
`cerebral infarct,
`tension, side-effects in
`the treatment of
`hypertension, a
`cerebral disorder,
`chronic pain,
`acromegaly,
`hypogonadism,
`secondary
`amenorrhea,
`premenstrual
`syndrome, undesired
`puerperal lactation, or
`combinations thereof
`…”
`
`IT IS FURTHER STIPULATED by the parties, pursuant to Exhibit A to the Joint Claim
`
`Construction Chart (D.I. 80), and subject to the approval of the Court, that the following
`
`constructions shall be given to the claim terms in the listed patents below:
`
`Terms for which the parties agree on claim construction
`
`Claim Term
`“treating”
`
`“is treated in the
`patient”
`
`Patent/Claim
`‘020 patent, claim 2;
`‘195 patent, claim 1
`‘804 patent, claim 1
`‘921 patent, claims 10, 12-14
`‘195 patent, claims 1
`‘804 patent, claim 1
`
`Stipulated Construction
`“attempting to cause a therapeutic
`effect on”
`
`“an attempt is made to cause a
`therapeutic effect in the patient”
`
`2
`
`
`
`Case 1:15-cv-00272-GMS Document 101 Filed 10/18/16 Page 3 of 6 PageID #: 1632
`
`Terms for which the parties agree no construction is required and plain and ordinary
`meaning should be applied
`
`Claim Term
`“hydrate”
`
`“anhydrate”
`
`“solvate”
`“dihydrochloride”
`“conventional”1
`
`Patent/Claim
`‘195 patent, claims 4-6;
`‘921 patent, claims 1, 5
`‘020 patent, claim 1
`‘195 patent, claims 3, 7
`‘804 patent, claim 1
`‘921 patent, claims 1-3, 5, 11
`‘921 patent, claims 1, 4
`‘921 patent, claim 1
`‘195 patent, claim 2
`‘804 patent, claim 1
`‘921 patent, claims 11, 15
`
`Clauses the parties agree are limiting
`
`Clause
`“wherein said patient is suffering from a depressive
`disorder”
`“wherein said patient is suffering from a major
`depressive disorder”
`“wherein the major depressive disorder is treated in
`the patient”
`“wherein a depressive disorder is treated in the
`patient”
`“wherein the depressive disorder is major depressive
`disorder”
`
`Patent/Claim
`‘020 patent, claim 4
`
`‘020 patent, claim 5
`
`‘804 patent, claim 1
`
`‘195 patent, claim 1
`
`‘195 patent, claim 16
`
`Clauses the parties agree are not limiting
`
`Clause
`“A method of treating a depressive disorder”
`“A method of treating a major depressive disorder”
`
`Patent/Claim
`‘195 patent, claim 1
`‘804 patent, claim 1
`
`The parties agree that these stipulated constructions apply only to the patents-in-suit, and
`
`have no bearing on the construction of claim terms in any other patent. Further, the stipulated
`
`constructions cannot be used as evidence against any party in any other pending or future suit.
`
`
`1 Defendants reserve the right to contend that this term is indefinite under 35 U.S.C. § 112.
`
`3
`
`
`
`Case 1:15-cv-00272-GMS Document 101 Filed 10/18/16 Page 4 of 6 PageID #: 1633
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`PHILLIPS GOLDMAN MCLAUGHLIN & HALL, P.A.
`
`/s/ David A. Bilson
`
`John C. Phillips, Jr. (#110)
`David A. Bilson (#4986)
`1200 North Broom Street
`Wilmington, DE 19806
`(302) 655-4200
`dab@pgmhlaw.com
`jcp@pgmhlaw.com
`
`Attorneys for Defendant Accord Healthcare
`Inc.
`
`OF COUNSEL:
`
`Jill M. Browning
`Michael J. Fink
`Neil F. Greenblum
`P. Branko Pejic
`Paul A. Braier
`GREENBLUM AND BERNSTEIN, P.L.C.
`1950 Roland Clarke Place # 100
`Reston, VA 20191
`(703) 390-1298
`
`/s/ Jack B. Blumenfeld
`_____________________________________
`Jack B. Blumenfeld (#1014)
`Maryellen Noreika (#3208)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@mnat.com
`mnoreika@mnat.com
`
`Attorneys for Plaintiffs Forest Laboratories,
`LLC, Forest Laboratories Holdings, Ltd.,
`Merck KGaA, and Merck Patent GmbH
`
`OF COUNSEL:
`
`David B. Bassett
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`(212) 230-8800
`
`Vinita Ferrera
`Emily R. Whelan
`Anna E. Lumelsky
`William C. Kinder
`Deric X. Geng, Ph.D.
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`60 State Street
`Boston, MA 02109
`(617) 526-6000
`
`4
`
`
`
`Case 1:15-cv-00272-GMS Document 101 Filed 10/18/16 Page 5 of 6 PageID #: 1634
`
`SMITH, KATZENSTEIN & JENKINS LLP
`
`/s/ Eve H. Ormerod
`
`Neal C. Belgam (#2721)
`Eve H. Ormerod (#5369)
`The Brandywine Building
`1000 West Street, Suite 1501
`P.O. Box 410
`Wilmington, DE 19899
`(302) 652-8400
`nbelgam@skjlaw.com
`eormerod@skjlaw.com
`
`Attorneys for Defendants Alembic
`Pharmaceuticals Ltd., Alembic Global
`Holding SA and Alembic
`Pharmaceuticals, Inc.
`
`OF COUNSEL:
`
`William O. Adams
`Karen M. Cassidy
`KNOBBE, MARTENS, OLSON & BEAR, LLP
`2040 Main Street, 14th Floor
`Irvine, CA 92614
`(949) 760-0404
`
`CAESAR RIVISE, PC
`
`/s/ R. Touhey Myer
`
`R. Touhey Myer (#5939)
`800 North King Street, Suite 304
`Wilmington, DE 19801
`(302) 544-9100
`tmyer@crbcp.com
`
`Attorneys for Defendant Invagen
`Pharmaceuticals Inc.
`
`OF COUNSEL:
`
`Robert S. Silver
`Salvatore Guerriero
`Lynn Terrebonne
`Pei-Ru Wey
`CAESAR RIVISE, PC
`1635 Market Street
`Seven Penn Center, 12th Floor
`Philadelphia, PA 19103
`(215) 567-2010
`
`5
`
`
`
`Case 1:15-cv-00272-GMS Document 101 Filed 10/18/16 Page 6 of 6 PageID #: 1635
`
`POTTER ANDERSON & CORROON, LLP
`
`MORRIS JAMES LLP
`
`/s/ Bindu A. Palapura
`
`/s/ Kenneth L. Dorsney
`
`Kenneth L. Dorsney (#3726)
`500 Delaware Avenue, Suite 1500
`Wilmington, DE 19801-1494
`(302) 888-6855
`Kdorsney@morrisjames.com
`
`Counsel for Defendants Apotex Inc. and Apotex
`Corp.
`
`OF COUNSEL:
`
`Richard T. Ruzich
`Stephen R. Auten
`Ian Scott
`TAFT STETTINIUS & HOLLISTER LLP
`111 East Wacker Drive, Suite 2800
`Chicago, IL 60601
`(312) 527-4000
`
`David E. Moore (#3983)
`Bindu A. Palapura (#5370)
`1313 North Market Street
`Hercules Plaza, 6th Floor
`P.O. Box 951
`Wilmington, DE 19899-0951
`(302) 984-6000
`dmoore@potteranderson.com
`bpalapura@potteranderson.com
`
`Attorneys for Defendant Teva
`Pharmaceuticals USA, Inc.
`
`OF COUNSEL:
`
`J.C. Rozendaal
`Michael E. Joffre
`Miles J. Sweet
`KELLOGG, HUBER, HANSEN, TODD,
` EVANS & FIGEL, P.L.L.C.
`1615 M Street NW, Suite 400
`Washington, DC 20036
`(202) 326-7900
`
`October 18, 2016
`
`SO ORDERED this
`
`day of October 2016.
`
`United States District Judge
`
`6
`
`